Very good news the placing has been a success. My assumptions were made in panic and this acquisition appears to be a great strategic move. My apologies, hope that there is little forward selling today.
Toying, You mention an acquisition, or is it a multi-national with interest; The reality is Ashman has cratered the S/P and raised at the current low of the year. Great product as you can contest but with naive management. Kind regards.
Elric, We accepted the reasoning not to go with the distributors for AxisB, this would have been the time to fundraise. AS has put his faith in securing a deal with a global partner. The company still has huge potential, but the CEO lacks a certain amount of acumen. I look forward to your response.
Choleric. You are beneath contempt. Psoriasis is not a condition with a monetary value but at least the company is alleviating the condition. You are a mean human being without dignity and morals.
What really rankles me is the company stated somewhere that they were in direct communication with the psoriasis communities of the UK and the US, without mention of a distributor as the go-between.
Excellent start to the day discussing a 3-week delay to end-of-year accounts. Bel you have certainly frightened the natives. Maybe it's time for you to interview Stuart.
Weave, Durex has shown strong interest in the CEO's strength, fortitude, and stamina with or without enhancement but the Chinese are waiting in the wings.
In reply Esco. Ricketts has taken part in the Chinese pilot scheme for a graphene-enhanced condom which is a micron in density. The rigidity enables the user 8 hours of usage, except in high humidity. This is a non-invasive product designed and tested repeatedly in both China and HQ.
RE: Good news, loan repayment delayed.6 Dec 2022 19:07
Fatherelmer, Ricketts sold his shareholding at £1.30, you should have done the same, this enterprise is and will extract your last penny. Best Wishes and sell into the next bull****.
Bel, I prefer to think that OPTI selling SBTX shares at the current price would further damage the S/P of both companies. Elric could you please elicit some Christmas cheer from SA.
If we give an average of £50 per order we have a sum of £202'255 for sales of AxisB based on order no;4051. If revenue from Croda brings in a further 200'000k the projection for the coming year then start to look attractive. Feasible or wishful thinking?